Anika Therapeutics Inc. (ANIK) Earnings Call Analysis

NASDAQ · Healthcare · Medical Instruments & Supplies

Earnings Reports

• ANIK Q2 2026: Gross Margin Climbs to 65% as Lean Transformation Drives Structural Profitability
  July 29, 2026
• Anika (ANIK) Q1 2026: Commercial Channel Up 12% as Integrity Adoption Accelerates
  April 29, 2026
• Anika (ANIK) Q4 2025: Commercial Channel Grows 22% as Integrity Adoption Doubles, Offsetting OEM Drag
  February 27, 2026
• Anika (ANIK) Q3 2025: Commercial Channel Jumps 22% as Integrity Platform Doubles Penetration
  November 05, 2025
• Anika (ANIK) Q2 2025: Integrity Drives 41% Regenerative Growth as Hyalofast Timeline Extends
  July 30, 2025
• Anika (ANIK) Q1 2025: Commercial Channel Grows 18% as OEM Pricing Headwinds Cut Margins
  July 06, 2025
• Anika Therapeutics (ANIK) Q1 2024: Cost Actions Unlock $10M Savings, Margin Improvement Drives EBITDA Turnaround
  August 08, 2024
• Anika (ANIK) Q1 2024: Cost Actions Unlock $10M Savings, Paving Way for 75% EBITDA Growth
  May 08, 2024
• Anika (ANIK) Q4 2023: $10M Cost Cuts and 75% EBITDA Jump Signal Accelerated Profitability Pivot
  March 13, 2024

Browse all companies